Trinity Delta is a leading provider of issuer-paid equity research for the healthcare and life sciences sectors. We have an experienced, integrated team of analysts providing the highest quality services to companies and to investors. Our expertise in biotech, medtech, specialty pharma and consumer health sectors enable a deep understanding of our clients and their ambitions, which is translated into accessible, impactful and timely research, clearly outlining the investment case.  Under MiFID II, whether you are an asset manager or a private investor, all can receive Trinity Delta research. Our research is paid for by our corporate clients and we do not carry out any execution business. Our reports are freely available to all investors via multiple platforms (see www.trinitydelta.org). We also firmly believe that by putting our clients first, we create long term value for all stakeholders.